SOUTH SAN FRANCISCO, Dec. 18 /PRNewswire/ -- Sunesis Pharmaceuticals, Inc. announced today that the Company has reached the first major milestone in the research collaboration initiated in May 2002 with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. This collaboration is focused on the discovery of small molecule enzyme inhibitors for the treatment of major chronic diseases, including inflammatory and autoimmune diseases. Sunesis achieved this milestone by discovering and delivering a novel lead series of compounds to Johnson & Johnson Pharmaceutical Research & Development. Sunesis will receive an undisclosed milestone payment. Based on the initial success of the program, Johnson & Johnson Pharmaceutical Research & Development will also increase its level of research funding support at Sunesis.
"Our success in reaching this milestone demonstrates our ability to rapidly identify novel lead compounds for important therapeutic targets," stated James Young, Ph.D., CEO of Sunesis. "We look forward to working closely with Johnson & Johnson Pharmaceutical Research & Development to advance this lead series as well as to identify additional small molecule leads."
Under the terms of this agreement, Sunesis receives research funding and will receive additional research and development milestones, as well as royalty payments upon the advancement and commercialization of small molecule enzyme inhibitors based on an exclusive, worldwide license to products resulting from the collaboration. The specific terms of the collaboration are undisclosed.
Sunesis is a leading discovery-based pharmaceutical company that applies its breakthrough fragment-based technologies to create superior oral therapeutics for the most challenging and important disease targets. Sunesis is building a pipeline of innovative therapeutics addressing major diseases through internal development and selective partnering... |
